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pendency using a non-linear analysis basedAIM: To propose a pharmacokinetic non-linear analysis method to determine contrast me-
dium (CM) dose for computed tomography (CT) hepatic enhancement to improve body size
dependency and validate the proposed CM dose determinationmethod through a clinical study.
MATERIALS AND METHODS: Enhancement data of 105 patients who underwent hepatic
dynamic CT with a fixed CM dose were analysed. From the analysis results, CM doses as a
function of each of four body size indices (body weight [BW], lean body weight [LBW], blood
volume [BV], and body surface area [BSA]) for achieving improved body size dependency were
determined (proposed method), and the body size dependencies were simulated using the
enhancement data from 105 patients. The proposed method was validated with a two-arm
clinical study on BW. Body size dependency was evaluated using p-value of correlation coef-
ficient between Body size indices and enhancements (p<0.05: significant dependency) and
mean absolute error (MAE).
RESULTS: The simulation showed that significant body size dependencies not considered by
the conventional method can be improved by the proposed method. MAEs of BW, LBW, and BV
were also significantly reduced (p<0.05). The clinical study with BW demonstrated a similar
improvement to that in the simulation result. MAE was also significantly reduced (p<0.001).
CONCLUSION: The proposed method demonstrated more improved BW, LBW, and BV
dependence compared to the conventional method. Through the two-arm clinical study, the
proposed method using BW only, without height information, is a suitable index for improving
body size dependency.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.* Guarantor and correspondent: K. Ichikawa, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa,
Ishikawa, 920-0942, Japan.u.ac.jp (K. Ichikawa).
Published by Elsevier Ltd. All rights reserved.
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T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx2IntroductionThe contrast medium (CM) dose is commonly adjusted
according to patient body weight (BW)1 in order to reduce
patient-to-patient variability in computed tomography (CT)
contrast enhancement and to prevent CM overdose.2,3
Although BW as a body size index is simple and easy to use,
CMdoses determined according to BWmaybe overestimated
in obese patients and underestimated in low-weight patients
becauseCMmigratespoorly through fat tissues.3e13 BW isnot
the only index for the determination of body size. Previous
studies have proposed and reported the use of body size
indices such as lean body weight (LBW), body mass index
(BMI), body surface area (BSA), and circulated blood volume
(BV), which could potentially improve body size dependency
during CM dose determination.3e13
Previous studies investigating the associations between
body size indices and contrast enhancement have
commonly assumed that there is a negative linear rela-
tionship between the two parameters. Specifically, for a
fixed amount of CM, contrast enhancement linearly de-
clines with an increase in body size. The linear correlation
coefficients can be estimated from linear approximation
and used to investigate the suitability of different body size
indices for contrast enhancement.4,7,8,10e13
One potential issue with this approach is that the rela-
tionship between body size indices and contrast enhance-
ment is not linear. According to pharmacokinetic principles,
body size indices and contrast enhancement have an intrin-
sically non-linear inverse relationship, where linear
assumption is a simplified approximation for estimating the
non-linear inverse relationship. When a drug (or CM) is
administered and distributed to the blood and body fluid
compartments, the drug or CM is more diluted in larger
compartments (larger body sizes), and thereby the concen-
tration is inversely proportional to the distribution volume.14
In CT imaging, a lower concentration of CM corresponds to
weaker contrast enhancement. Thus, for a fixed amount of
CM, CT contrast enhancement changes with body size ac-
cording to a non-linear inverse relationship. Furthermore,
according to a physiologically based pharmacokinetic com-
puter simulation used to analyse contrast enhancement in
various organs (multicompartment model), the inversely
proportional relationship is present inboth the aorta and liver
and maintained from the early arterial to the equilibrium
phases.15 Therefore, it is important to consider approaches
beyond linear assumption in order to take into account non-
linear contrast enhancement.
Previous studies have proposed multi-linear associations
between body size indices and CT contrast enhancement.4,5
Specifically, Kondo et al. performed a multi-linear regression
analysis on the association between BW and hepatic contrast
enhancement with non-linear inverse relationships between
bodysize indexandCTcontrastenhancement.4Different linear
slopeswereobtainedfor theBWgroups; the lowBWgrouphad
a higher slope than the high BW group. Bae et al. divided pa-
tients into low and high BMI groups and applied a regression
analysis to investigateassociationsof aortic enhancementwithPlease cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principlBW, BMI, and BSA.5 The study found that the lowandhigh BMI
groups showed significantly different regression slopes and
that the amount of CM required with increased body size was
lower in the high BMI group than in the low BMI group;
however, limitations of these studies are that the non-linear
properties were assumed to be only due to poor CM migra-
tion of fat tissues in obese patients, not taking into account the
pharmacokinetic non-linear inverse relationship.
The present study aimed to propose a pharmacokinetic
non-linear analysis to determine CM dose for hepatic
enhancement, taking into account the non-linear inverse
relationship between body size indices and CT contrast
enhancement, in order to improve body size dependency. In
addition, a second aimwas to validate the proposedmethod
for determining CM dose through a clinical study.
Materials and methods
Contrast medium dilution, enhancement, and body size
Fig 1 graphically describes the inverse association be-
tween body size index, B, which is assumed to be propor-
tional to the distribution volume, V, of CM and contrast
enhancement, E, for a fixed dose of CM. Thus, this inverse




where m is CM dose, k¼constant (i.e. V¼kB) and E is the
contrast enhancement. In cases using CM doses (m) that are
proportional to B, the association between B and E/m
(contrast enhancement/iodine dose) is similarly inversely
proportional. Note that an association with inverse pro-
portionality indicates a non-linear curve with negative
slopes as shown in Fig 1a and is different from the negative
linear association (dotted line in Fig 1a) that has been
assumed in the linear regression analysis in the previous
studies. Furthermore, this inversely proportional associa-
tion corresponds to the linear function of the CM dose
determination for a target uniform enhancement ET (Fig 1b),
which is apparent by substituting ETkB form in equation (1).
When the association is negative and linear, as in E¼eaB þ
b, the CM dose for uniform E should not be proportional
to B, but rather non-linear against B as shown in the dotted
line in Fig 1b; that is, the negative linear assumption for the
relationship between B and E (E/m) is inconsistent with the
widely used CM administration method (conventional
method) where CM dose is proportional to B (e.g., 0.6 g
iodine/kg (g I/kg) for BW or 18 g I/m2 for BSA). Conse-
quently, non-linear regression analysis for the association
between B and E (or E/m) appears to be more reasonable for
describing the association.
Non-linear regression analysis and simulation of body
size dependency
Patients
The non-linear regression analysis is based on results
from a clinical study approved by the institutional internalium dose for hepatic CT enhancement with improved body size de-
es, Clinical Radiology, https://doi.org/10.1016/j.crad.2019.09.140
Figure 1 (a) Constant iodine mass with two different body size indices B, resulting in two different enhancements E in a non-linear (inverse
proportional) relationship. Dotted line: linear approximation. m denotes contrast material dose and k is a constant. (b) To obtain a constant
enhancement Econst, the iodine mass should be adjusted such that it is proportional to B, which is consistent with the inverse proportionality in
(a). Thus, linear approximation [dotted line in (a)] is inconsistent with the linear iodine mass adjustment and corresponds to a non linear
adjustment [dotted line in (b)].
T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx 3review board and informed consent was obtained from all
participants. The study group comprised 105 patients (56
men, 49 women; age, 28e93 years; mean age, 66.713.5
years) with a history of gastrointestinal cancer who un-
derwent follow-up contrast-enhanced dynamic CT, carried
out between May and December 2017. The following types
of gastrointestinal cancer were included: colorectal cancer
(n¼56), gastric cancer (n¼41), oesophageal cancer (n¼3),
pancreatic cancer (n¼3), and gallbladder cancer (n¼2). Pa-
tients with a history of chronic underlying liver disease
(cirrhosis, fatty liver) were excluded. The range of patient
BWs was 29e92 kg (mean: 58.414.5 kg) and height range
was 135e178 cm (mean: 159.89.7 cm), respectively.
CM administration. All patients received 100 ml (30 g)
of non-ionic iodine CM, iopamidol, containing 300 mg
iodine/ml (Iopamiron 300; Bracco, Milan, Italy) through 20-
G plastic intravenous catheters placed in an antecubital
vein, followed by a 30-ml saline flush. The rate of intrave-
nously injected CM was 3 ml/s with an automatic power
injector (Dual Shot GX; Nemoto Kyorindo, Tokyo, Japan).
Therefore, CM was injected for a fixed duration of 33
seconds.
CT imaging. All patients were scanned using a 320-slice CT
system(AquilionONE,Canonmedical systems,Tochigi, Japan).
The imaging parameters were as follows: 321 mm detector
configuration, 0.844 beam pitch, 0.5 seconds rotation time, 5
mm slice thickness, and 5 mm reconstruction interval. The
automatic tube current modulation function, volume EC, was
used with a noise index of 12 at 120 kV.Please cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principlFollowing the unenhanced scanning, contrast-enhanced
dynamic scanning was started after the injection of CM
with a delay of 80 seconds to achieve hepatic enhancement
at the late portal phase. The unenhanced and contrast-
enhanced scans were performed using the same imaging
parameters described above.
Measuring hepatic enhancement. Mean CT values in he-
patic parenchyma at three different hepatic segments (right
lobe, medial segment, and left lobe at the slice level of the
main portal vein) were measured by T.H. (20 years of CT
operation experience). Circular regions of interest (ROIs;
range: 10e20 mm; mean: 14.8 mm) were placed on unen-
hanced and enhanced images. Focal hepatic lesions, blood
vessels, bile ducts, calcifications, and artefacts were care-
fully excluded from ROI placements. Hepatic enhancement
for each ROI was calculated by subtracting the ROI value on
the unenhanced image from that on the contrast-enhanced
image.
Body size indices. For the non-linear regression analysis,
BW, LBW, BV, and BSA were adopted as the body size
indices. The patient’s height used to calculate LBW and BV,
and BSAwas acquired from the patients’medical charts. BW
was measured right before CT. LBW (kg) was calculated
using the following formulas:16,17
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where H¼height (m) and W¼body weight (kg). BV (L) was
calculated using the following formulas:18
BVðmaleÞ ¼ 0:168H3 þ0:050W þ 0:444
BVðfemaleÞ ¼ 0:250H3þ 0:063W  0:662
The following formula19 was used for estimating BSA
(m2):
BSA ¼ W0:444  H0:663  0:008883
Method of non-linear analysis. Non-linear regression
analysis based on the previously mentioned pharmacoki-
netic principles (non-linear analysis) on plots of the
measured hepatic enhancement versus each body size in-
dex was performed. The following equation modified from
equation (1), where b¼adjustment coefficient, was used:
E ¼ m
kBþ b (2)
The adjustment coefficient was introduced to improve
fitting flexibility of the non-linear analysis, where the b-
value becomes a sufficient small value when B is precisely
proportional to V. The fitting of the non-linear regression
was performed based on the least squares method. The k
and b parameters were optimised to obtain the best-fitted
results that minimise the residual sum of squares between
measured and estimated E values on the fitted curve. The
CM dose m in grams was set to 30, corresponding to the
fixed CM dose administered. Using the obtained k and b
values, the CM dose for a target uniform enhancement ET
can be estimated by the following calculation:
m ¼ ETðkBþ bÞ (3)
which is obtained by substituting ET (kB þ b) for m in
equation (2). Thus, CM dose is adjusted by both the slope
(ETk) and intercept (ETb) rather than only by a proportion-
ality constant that has been set at a value such as 0.6 g
iodine/kg in the conventional method.
Simulation of body size dependency. As mentioned earlier,
the conventional method, in which the CM dose is simply
proportional to BW, is problematic in that BW dependency of
hepatic enhancement occurs (over enhancements for obese
patients and under-enhancements for low-weight patients).
Thus, simulations were performed to evaluate whether the
proposed CMadministrationmethodbasedon thenon-linear
analysis could reduce the dependency for each body size in-
dex, and the effectiveness of LBW, BV, and BSA to reduce the
body size dependency was verified. According to the funda-
mental principle of CM dilution in the body,1,2 hepatic
enhancement is proportional to the CM dose. Thereby,
simulated enhancement ESwas estimated from themeasured
enhancementEMwith the30-gfixedCMdose, bya calculation
of EM(m’/30), where m’ denotes an assumed CM dose forPlease cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principleach patient, estimated using equation (3). ET (target
enhancement) in theequationwasset to50HUfor thedesired
hepaticenhancement, aspreviously reported.1Conversely, for
Es calculation corresponding to the conventionalmethod, the
assumed CMdosem’ for the same ETwas estimated using the
adjusted hepatic enhancement (AHE) proposed by Heiken
et al.,1 which is the basis of the conventional method. AHE is
the enhancement when 1 g of iodine per unit of BW (kg) is
administered; thus,m’ for ET can be estimated using the AHE
calculation. For theotherbodysize indices (LBW,BV,andBSA),
m’wasdeterminedusing each index instead of BW in theAHE
calculation.
The correlation coefficient with p-values and mean ab-
solute error (MAE) were used for ET, obtained from the
relationship between B and ES, as indices for evaluating the
body size dependency. Higher dependency (worse patient-
to-patient uniformity) was indicated as a correlation coef-
ficient with p<0.05 and a greater MAE. The significance of
differences in MAE between the simulation results of pro-
posed and conventional methods was evaluated by using a
two-tailed Student’s t-test in Excel 2010 (Microsoft, Red-
mond, WA, USA). A p-value of <0.05 indicated a significant
difference.
Clinical study comparing proposed and conventional CM
administration methods
A clinical study was conducted comparing the proposed
method based on the results of the non-linear analysis and
the conventional method. The study was approved by the
institutional internal review board, and informed consent
was obtained from all patients. The study group comprised
200 patients (114 men, 86 women; age, 30e94 years; mean
age, 67.511.6 years) who underwent follow-up contrast-
enhanced dynamic CT between July 2017 and June 2018.
Patients were randomly assigned to undergo either the
conventional CM administration (conventional method
group) or the proposed CM administration (proposed
method group) in which the CM dose was determining
using the equation (3); consequently, 100 patients were
enrolled in each group. The body size index used was BW.
Patient history, exclusion criteria, CT parameters, and
measurement method of hepatic enhancement were the
same as those for the earlier mentioned studywith the fixed
CM dose.
Body size dependency was evaluated using the same
method described in the simulated enhancement. The cor-
relation coefficient and MAE were compared between the
conventional and proposed method groups.
Results
Non-linear analysis
Fig 2 shows the scatter plots of E versus B for each body
size index, including the fitted curve obtained from the
non-linear analyses. The resultant k and b values (k/b) of
BW, LBW, BV, and BSA were 0.0089/0.194, 0.0109/0.201,ium dose for hepatic CT enhancement with improved body size de-
es, Clinical Radiology, https://doi.org/10.1016/j.crad.2019.09.140
Figure 2 Scatter plots of each body size index versus hepatic enhancement, including resultant fitting curve of non-linear regression analysis
(non-linear analysis). (a) BW, (b) estimated LBW, (c) estimated circulated BV, and (d) estimated BSA. A fixed CM dose of 30 g was administered to
each patient; then the hepatic enhancement was measured at a portal phase.
T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx 50.1264/0.196, and 0.539/-0.138, respectively. CM adminis-
tration functions for ET of 50 HU, calculated using k and b
values and equation (3) were as follows:
BW (kg): m¼0.447BW þ 9.7 (4)
LBW (kg): m¼0.547LBW þ 10.1 (5)
BV (L): m¼6.32BV þ 9.8 (6)
BSA (m2): m¼27BSA e 6.9 (7)
These equations were used for the ES calculations.
Simulated body size dependency
Figs 3 and4 show the scatter plots indicating the simulated
body size dependencies of hepatic enhancement for the
proposedand conventionalmethods, respectively. The results
of correlation coefficients andMAEs are shown inTable 1. The
proposed method showed improved patient-to-patientPlease cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principluniformity by taking into account body size dependencies,
thus presenting generally flat regression lines. Although LBW
indicated the largest correlation coefficient, the difference
between body size indices appeared not to be remarkable. In
contrast, the results of the conventionalmethodshowedbody
size dependences have significantly reduced the patient-to-
patient uniformity for all body size indices (p<0.001 for BW,
LBW, and BV; p¼0.025 for BSA), i.e., hepatic enhancement
tended to increase with not only BW, but also LBW and BV
under the conventional method. BSA showed a negative de-
pendency. Although BW indicated the largest correlation co-
efficient of 0.440, LBWand BV also showed comparably large
values of 0.385 and 0.390, respectively. The MAE value of the
proposed method was significantly smaller than that of the
conventional method, except for BSA, by which improved
body size dependencies of BW, LBW, and BV under the pro-
posed method were demonstrated.Clinical study comparing proposed and conventional CM
administration methods
Patient age and BW of the proposed method and con-
ventional method groups (proposed/conventional) wereium dose for hepatic CT enhancement with improved body size de-
es, Clinical Radiology, https://doi.org/10.1016/j.crad.2019.09.140
Figure 3 Scatter plots of simulated hepatic enhancement for evaluating body size dependency of proposed CM administration method based on
the non-linear analysis. The target enhancement ET was set to 50 HU. (a) BW, (b) LBW, (c) BV, and (d) BSA. The generally flat regression lines
indicated improved body size dependencies detailed in Table 1.
T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx631e93 (67.712.4)/30e94 (67.410.8) and 30.4e82.5 kg
(56.612.4 kg)/32.6e82 kg (59.111.9 kg). The CM dose
administration function for ET of 40 HU, calculated from
k and b values for BW, was m¼0.355BW þ 7.7. CM doses
determined using this function were administered to the
proposed method group. Fig 5 shows the identified re-
lationships between BW and hepatic enhancement for the
proposed method and conventional method groups. Table 2
shows detailed results from the scatter plots. As predicted
in the simulated enhancement (Figs 3 and 4), the proposed
method group results took into account BW dependency of
hepatic enhancement with a low correlation coefficient of
e0.086 with p¼0.347, while the conventional method
group did not with a correlation coefficient of 0.440 with
p<0.001; the MAE value was significantly reduced by the
proposed method (p<0.001). ET of 40 HU was chosen
because the CM concentrations of syringe products that
could be used were limited, and the estimated enhance-
ment of the assumed heaviest BWof 100 kg was 40 HU. BW
was used because its correlation coefficient and MAE in
Table 1 was the smallest. A coefficient of 0.494 g iodine/kg
was used for the conventional method group, determined
based on the AHE calculation mentioned in the simulationPlease cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principlmethod. Table 3 shows CM doses for BWs from 40 to 99 kg
divided into six ranges, administered in the proposed and
conventional methods for ET of 40 HU.Discussion
The clinical study comparing the conventional and pro-
posed CM administration methods with BW demonstrated
that the proposed method significantly improved the body
size dependence, as predicted in the simulation with BW.
Thus, combining this good agreement between the clinical
study result and the prediction and that Es is calculated
based on the established contrast enhancement propor-
tionality to CM dose, ES is considered as a good predictor for
patient-to-patient uniformity for each body size index.
From the simulation results assuming the conventional
method (Fig 4), not only BW but also LBW, BV, and BSAwere
not effective for improving the body size dependency
because of the larger correlation coefficients with p<0.05
and large MAEs. In contrast, the simulation using the pro-
posed method (Fig 3) presented the sufficiently small cor-
relation coefficients (not significant body size dependency)ium dose for hepatic CT enhancement with improved body size de-
es, Clinical Radiology, https://doi.org/10.1016/j.crad.2019.09.140
Figure 4 Scatter plots of simulated hepatic enhancement for evaluating body size dependency of conventional CM administration method
(conventional method) based on adjusted hepatic enhancement (AHE) analysis. (a) BW, (b) LBW, (c) BV, and (d) BSA. The inclined regression lines
of all body size indices and detailed results in Table 1 indicated significant body size dependencies.
Table 1
Correlation coefficients and mean absolute errors (MAEs) on the relationship between each body size index and simulated enhancement shown in Figs 3 and 4.
Proposed method Conventional method p-Value
BW Correlation coefficient (p-Value) e0.015 (0.876) 0.440 (<0.001) n/a
MAE (HU) 6.313 7.030 <0.05
LBW Correlation coefficient (p-Value) 0.070 (0.479) 0.385 (<0.001) n/a
MAE (HU) 6.914 7.497 <0.05
BV Correlation coefficient (p-Value) e0.026 (0.796) 0.390 (<0.001) n/a
MAE (HU) 6.318 6.979 <0.05
BSA Correlation coefficient (p-Value) e0.019 (0.841) e0.219 (0.025) n/a
MAE (HU) 6.391 6.638 0.100
BW, body weight; LBW, lean body weight; BV, circulated blood volume; BSA, body surface area.
The dependency was improved from the significant correlations of at least p<0.05 in the conventional method to no significant correlations in the proposed
method. Mean absolute error (MAE) was significantly reduced by the proposed method, except for body surface area.
T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx 7and the smaller MAEs, although BSA did not present a sig-
nificant MAE difference (Table 1). Thus, the results indicated
that the body size dependencies of LBW, BV, and BSA could
be improved by the proposed method, similarly to BW. It
should be noted that these three indices are not necessarily
more advantageous compared with BW under the CM ad-
ministrations using the proposed method, which suggested
that BW is more easy to use than the other indices requiring
the measurement or information regarding patient height.
The scatters plots, which were presented in both the ESPlease cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principlanalysis and clinical study, were seemingly caused by
various physical factors such as cardiac output and hydra-
tion status3,11 and should be investigated further in a future
study. Further studies should focus on improvements using
techniques that are more sophisticated and can detect in-
dividual vascular conditions.
The non-linear analysis is based on the inverse propor-
tionality corresponding to the CM dilution principle in V
(distribution volume for CM), as mentioned in Introduction.
Therefore, when a body size index is more preciselyium dose for hepatic CT enhancement with improved body size de-
es, Clinical Radiology, https://doi.org/10.1016/j.crad.2019.09.140
Figure 5 Scatter plots of BW versus hepatic enhancement obtained through a clinical study using (a) the proposed and (b) conventional CM
administration methods for a target enhancement of 40 HU. The significant BW dependency (inclined regression line) of the conventional
method was improved by the proposed method indicating a flat regression line.
Table 2
Detailed results of body weight dependency for a clinical study using the proposed and conventional contrast medium administration methods.
Proposed method Conventional method p-Value
Average enhancement (HU) 394.4 38.45.6 0.574
Correlation coefficient (p-Value) e0.086 (0.347) 0.440 (<0.001) n/a
MAE (HU) 4.354 6.630 <0.001
Table 3
CM doses for BWs from 40 to 99 kg divided into six ranges, used in the proposed and conventional methods for a target enhancement of 40 HU.
40e49 kg 50e59 kg 60e69 kg 70e79 kg 80e89 kg 90e99 kg
Proposed method (g iodine) 21.9e25.1 25.5e28.6 29e32.2 32.6e35.7 36.1e39.3 39.7e42.8
Conventional method (g iodine) 19.8e24.2 24.7e29.1 29.6e34.1 34.6e39.0 39.5e44 44.5e48.9
T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx8proportional to V, the regression becomes more precise and
the b-value becomes closer to zero; however, in the present
results, all b values were not near zero, suggesting that LBW,
BV, and BSA, which have been investigated as alternatives to
BW, were not adequately proportional to V. As a result, the b
values yielded bias doses (intercept) calculated by ETb as
indicated in equations (4)e(7) and contributed to
compensate the insufficient proportionality, as in the sim-
ulations (Fig 3) and the clinical study with BW (Fig 5a). For
BW, to compensate the overdosing in obese patients and the
under-dosing in low-weight patients in the conventional
method, decreasing and increasing coefficients in CM dose
determination are needed, respectively. The bias dose
contributes to these needs as it reduces the slope for obese
patients, compared with the conventional method, and
simultaneously ensures the required CM dose for light pa-
tients. It should be noted that the slope and bias values in
the proposed method were determined quantitatively
through pharmacokinetic non-linear analysis and first
principles rather than from an empirical estimate.
This study has several limitations. First, the clinical
validation of the proposed CM administration method was
only performed for BW. Although the simulation results
using ES indicated that these indices can improve the bodyPlease cite this article as: Hibino T et al., Determination of contrast med
pendency using a non-linear analysis based on pharmacokinetic principlsize dependency similarly to BW, it should be confirmed in
actual clinical studies. Second, the non-linear regression
was based on a patient cohort of 105 and the sample size
can be increased to improve accuracy of the analysis as the
fitting results might vary depending on the variability be-
tween patients, possibly affecting the calculation accuracy
of the CM administration functionwith bias. The non-linear
analysis can be performed using the relationship between B
and ‘E/m’, which means that data for the analysis can be
continuously increased with E/m data obtained using pro-
tocols for either the conventional or proposed method.
Additionally, as the population enrolled is solely in Japan,
studies should be performed in other regions worldwide to
include a more diverse patient population. An interesting
area would be to apply the present methods in obese pa-
tients. Lastly, hepatic enhancement was investigated only at
80 seconds post-injection because enhancement decay at
approximately 80 seconds is empirically known to be very
slow; however, variations in enhancement timing between
individuals caused by differences in physical factors were
included in the enhancement data, possibly affecting the
regression analysis.
In conclusion, the non-linear analysis including adjust-
ment coefficient b for the association between B and E andium dose for hepatic CT enhancement with improved body size de-
es, Clinical Radiology, https://doi.org/10.1016/j.crad.2019.09.140
T. Hibino et al. / Clinical Radiology xxx (xxxx) xxx 9the analysis results (k and b values) were used to determine
CM doses for improving the body size dependence (the
patient-to-patient uniformity) compared to negative linear
regression analysis commonly used previously. The ES and
clinical study results indicated that the proposed CM
administration method based on non-linear analysis, which
consequently formed a linear function with a bias dose,
more significantly improves the body size dependency of
hepatic enhancement than the conventional method. The
proposed CM administration method using BW sufficiently
improved the contrast enhancement dependency on BW,
which has been discussed in previous studies seeking
suitable other body size indices.
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